Skip to main content

Table 2 NR2F1 expression and clinical outcome

From: NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients

 

Fraction of DTCs categorized as NR2F1high

Distant metastasis (all) or death from breast cancer (%)

Bone metastasisb (%)

All patientsa (n = 26)

< 50%

0 to < 50% NR2F1high

17/19 (89.5)

10/15 (66.7)

0–1% NR2F1high

13/15 (86.7)

9/14 (64.3)

50–100%

4/7 (57.1)

2/7 (28.6)

Patients without metastasis prior to last DTC-positive BMA and no negative DTC status at subsequent BMA (n = 18)

< 50%

0 to < 50% NR2F1high

13/14 (92.9)

9/12 (75.0)

0–1% NR2F1high

11/12 (91.7)

8/11 (72.7)

50–100%

1/4 (25.0)

1/4 (25.0)

Patients with no metastasis at time point for last DTC-positive BMA, no negative DTC status at subsequent BMA, and no chemotherapy after the BM analysis (n = 14)

< 50%

0 to < 50% NR2F1high

11/12 (91.7)

7/10 (70.0)

0–1% NR2F1high

9/10 (90.0)

6/9 (66.7)

50–100%

1/2 (50.0)

1/2 (50.0)

  1. If analysis was performed at more than one time point, the last disseminated tumor cell (DTC)-positive sample is included
  2. BMA bone marrow aspirate
  3. aIncludes results from 4 patients with metastases detected before bone marrow (BM) analysis and 8 patients receiving chemotherapy after the BM analysis
  4. bNo information on bone metastasis status was available from four patients in total